On November 30, 2021, the FDA’s advisory panel voted to recommend the emergency use authorization of Merck’s antiviral medication molnupiravir. If approved, this would be the first oral agent available for the treatment of patients with mild to moderate COVID-19. Molnupiravir works by incorporating itself into the SARS-CoV-2 viral RNA to inhibit replication of the virus. After evaluating safety and efficacy data provided by Merck, the FDA panel voted 13-10 to approve the use of molnupiravir under emergency use authorization. The drug was studied in a Phase 3 trial which enrolled non-hospitalized patients 18 years and older, within 5 days of symptom onset of mild to moderate COVID-19 disease, who were at high risk for severe illness. Patients receiving molnupiravir were given either 200, 400, or 800 mg or placebo orally every 12 hours for 5 days. The primary endpoint of the study, percentage of participants with all cause hospitalization or death through day 29, was found to be 7.3% in the molnupiravir group and 14.1% in the placebo group. Molnupiravir was overall well tolerated with an acceptable safety profile. Treatment with molnupiravir should be started within 5 days of symptom onset. Although molnupiravir was primarily studied in patients who were infected with the Delta, Mu, and Gamma variants of COVID-19, there is belief that because of its mechanism of action, it would provide a similar benefit against the Omicron variant. Molnupiravir is not meant to be an alternative to vaccination, but simply provides another treatment option to reduce the risk of hospitalization or death in those who are infected by COVID-19.